Dr. Bazhenova On The Pacific Trial With Durvalumab In Nsclc

Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLC

PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC

Durvalumab Consolidation in NSCLC: The PACIFIC Trial

Targeted Oncology

PACIFIC 6: durvalumab after sCRT in patients with NSCLC

PACIFIC trial updates: durvalumab after chemotherapy in NSCLC

Durvalumab: the new standard of care for NSCLC?

Dr. Simon on Durvalumab for Patients With Lung Cancer

Results from the PACIFIC study: durvalumab with chemoradiation for the treatment of NSCLC

PACIFIC-R: real-word durvalumab after chemo-RT in stage 3 NSCLC

Durvalumab improves PFS in stage III lung cancer

Dr. Bazhenova on Ongoing Clinical Trials With Immunotherapy in NSCLC

Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC

POSEIDON: durvalumab +/- tremelimumab + chemo in 1L mNSCLC

PACIFIC Trial: Durvalumab for Stage 3 NSCLC

Dr. Feldman on Durvalumab for Patients With Lung Cancer

Dr. Spigel on the Rationale Behind the PACIFIC Trial

Reactions to the PACIFIC Trial in Stage III NSCLC

Refining which patients benefit from consolidation durvalumab for stage III unresectable NSCLC

PACIFIC trial of durvalumab for stage III NSCLC

Results for Durvalumab in the Second-Line Treatment of NSCLC

Targeted Oncology